These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7285527)

  • 21. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
    Facca A; Sanchez-Ramos J
    Mov Disord; 1996 May; 11(3):327-9. PubMed ID: 8723153
    [No Abstract]   [Full Text] [Related]  

  • 22. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa.
    Sternberg EM; Van Woert MH; Young SN; Magnussen I; Baker H; Gauthier S; Osterland CK
    N Engl J Med; 1980 Oct; 303(14):782-7. PubMed ID: 6997735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
    Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carbidopa dosage modifies L-dopa induced side effects and blood levels of L-dopa and other amino acids in advanced parkinsonism.
    Bermejo Pareja F; Martinez-Martin P; Muradas V; de Yébenes JG
    Acta Neurol Scand; 1985 Nov; 72(5):506-11. PubMed ID: 4082917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absorption of orally disintegrating carbidopa-levodopa requires intact small bowel function.
    Iyer SS; Morgan JC; Sethi KD
    Neurology; 2005 Nov; 65(9):1507. PubMed ID: 16275853
    [No Abstract]   [Full Text] [Related]  

  • 26. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Value of low-dose dopa therapy in Parkinson disease].
    Petit H; Rousseaux M; Mazingue A; Warot P
    LARC Med; 1983; 3(7):514-6. PubMed ID: 6645742
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of complicated Parkinson disease with a solution of levodopa-carbidopa and ascorbic acid].
    Linazasoro G; Gorospe A
    Neurologia; 1995; 10(6):220-3. PubMed ID: 7546811
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease.
    Westin J; Nyholm D; Groth T; Dougherty MS; Yerramsetty PK; Palhagen SE
    Parkinsonism Relat Disord; 2006 Dec; 12(8):509-13. PubMed ID: 16731025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Case report: successful use of rectally administered levodopa-carbidopa.
    Cooper SD; Ismail HA; Frank C
    Can Fam Physician; 2001 Jan; 47():112-3. PubMed ID: 11212422
    [No Abstract]   [Full Text] [Related]  

  • 31. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
    Chaná P; Fierro A; Reyes-Parada M; Sáez-Briones P
    Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
    Zimmerman TR; Sage JI; Lang AE; Mark MH
    Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A year of treatment with carbidopa and levodopa in Parkinsonian patients].
    Martínez-Lage JM; Marti-Massó JF; Delgado G; Carreray N; Del Amo F
    Rev Clin Esp; 1974 Sep; 134(6):535-42. PubMed ID: 4450036
    [No Abstract]   [Full Text] [Related]  

  • 34. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anticholinergics and dyskinesia.
    Linazasoro G
    Mov Disord; 1994 Nov; 9(6):689. PubMed ID: 7845412
    [No Abstract]   [Full Text] [Related]  

  • 36. Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.
    Metman LV; Hoff J; Mouradian MM; Chase TN
    Mov Disord; 1994 Jul; 9(4):463-5. PubMed ID: 7969216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Soft tissue-anchored transcutaneous port attached to an intestinal tube for long-term gastroduodenal infusion of levodopa/carbidopa in Parkinson disease.
    Nyman R; Lundgren D; Nyholm D
    J Vasc Interv Radiol; 2009 Apr; 20(4):500-5. PubMed ID: 19216094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Combined treatment of parkinsonism with L-dopa and Parkopan].
    Lukasiewicz K
    Wiad Lek; 1977 May; 30(10):775-7. PubMed ID: 867994
    [No Abstract]   [Full Text] [Related]  

  • 39. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease.
    Nyholm D
    Expert Rev Neurother; 2006 Oct; 6(10):1403-11. PubMed ID: 17078781
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acetazolamide therapy of menstrual-related fluctuations in Parkinson's disease.
    Factor SA
    Mov Disord; 1993 Apr; 8(2):240-1. PubMed ID: 8474504
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.